V1RC19 Inhibitors
V1RC19 inhibitors are a class of chemical compounds that have been identified for their specific molecular interaction with a particular target known as V1RC19, a protein or enzyme pivotal in certain biochemical pathways. The inhibitors are designed to bind to the active site or another critical region of the V1RC19 protein, thus inhibiting its natural function within the biological system. The structure of these inhibitors is often complex, reflecting the need for a high degree of specificity to ensure that they interact with the V1RC19 protein in the intended manner without affecting other proteins or enzymes within the system. This specificity is achieved through a careful design process that may involve the identification of unique binding pockets or allosteric sites on the V1RC19 protein that are not present on other proteins.
The development of V1RC19 inhibitors involves extensive research into the structure and function of the V1RC19 protein, including its three-dimensional conformation, the dynamics of its active site, and its role within its respective biological pathway. By understanding these elements, chemists can design inhibitors that are not only potent in their action but also exhibit high selectivity, minimizing interactions with other proteins and reducing the likelihood of off-target effects. V1RC19 inhibitors are typically characterized by their binding affinity, which is a measure of how tightly and effectively they bind to the V1RC19 protein, as well as by their kinetic properties, such as how quickly they bind to and dissociate from the target. The molecular architecture of these inhibitors often includes moieties that mimic the natural substrate of the V1RC19 protein or otherwise interact with key amino acid residues within the binding site, enabling the inhibitor to effectively compete with the natural substrate for binding to the V1RC19 protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
This synthetic nucleoside analog interferes with the replication of RNA viruses by inhibiting inosine monophosphate dehydrogenase, ultimately leading to a depletion of guanosine triphosphate and impeding the replication of V1RC19. | ||||||
Sofosbuvir | 1190307-88-0 | sc-482362 | 25 mg | $143.00 | 1 | |
Sofosbuvir is metabolized to an active uridine analog triphosphate form that inhibits the NS5B protein, a viral RNA-dependent RNA polymerase, which is crucial for the replication of V1RC19. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $47.00 | ||
Zinc ions are known to inhibit the activity of RNA-dependent RNA polymerase, an essential enzyme for V1RC19 replication. Zinc acetate can act as a source of zinc ions, thus potentially inhibiting V1RC19 activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is known to increase endosomal pH, which can inhibit virus-cell fusion, an essential step in the life cycle of V1RC19. By blocking entry, it indirectly prevents V1RC19 from initiating its replication process. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Similar to chloroquine, hydroxychloroquine raises endosomal pH and inhibits the glycosylation of cellular receptors of SARS-CoV-2. This inhibits the virus from entering host cells, thereby reducing V1RC19 activity. | ||||||
Ivermectin | 70288-86-7 | sc-203609 sc-203609A | 100 mg 1 g | $56.00 $75.00 | 2 | |
Ivermectin has been shown to inhibit the importin α/β1 nuclear transport proteins, which are part of a critical intracellular transport process that viruses like V1RC19 hijack to enhance infection. Inhibiting this pathway decreases V1RC19 activity. | ||||||
Lopinavir | 192725-17-0 | sc-207831 | 10 mg | $129.00 | 6 | |
Lopinavir is a protease inhibitor that can impede the processing of viral polyproteins, essential for the maturation of V1RC19. Without proper processing, V1RC19 remains non-infectious. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
Ritonavir acts as a pharmacokinetic enhancer of lopinavir by inhibiting the cytochrome P450 3A4 enzyme that metabolizes lopinavir, leading to increased levels of lopinavir and potentiated inhibition of V1RC19 maturation. | ||||||
Apilimod | 541550-19-0 | sc-480051 sc-480051A | 100 mg 1 g | $420.00 $2600.00 | 5 | |
Apilimod inhibits PIKfyve kinase, which is involved in the production of phosphatidylinositol 3-phosphate necessary for early endosome formation. V1RC19 requires endosomes for cell entry and replication, so inhibition of this process can reduce its activity. | ||||||
Nitazoxanide | 55981-09-4 | sc-212397 | 10 mg | $122.00 | 1 | |
Nitazoxanide interferes with the pyruvate:ferredoxin oxidoreductase enzyme, which is essential in anaerobic energy metabolism. While not directly linked to V1RC19, it is posited that disrupting host cellular processes can indirectly inhibit V1RC19 replication. | ||||||